Citations

Clear

3030 citation(s) found for "Susan, M".

Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma
García, Héctor Alexander Velásquez , Spinelli, John J., Gaffney, Patrick M. , Smedby, Karin E. , Wang, Sophia , Adami, Hans‐Olov , Angelucci, Emanuele , Ansell, Stephen M. , Asmann, Yan W. , Becker, Nikolaus, Benavente, Yolanda , Berndt, Sonja I. , Bertrand, Kimberly A. , Birmann, Brenda M. , Boeing, Heiner , Bracci, Paige M. , Brennan, Paul , Brooks‐Wilson, Angela , Clavel, Jacqueline , Conde, Lucía , Cotenbader, Karen H, Cox, David G. , Crouch, Simon , Roos, Anneclaire J. De , Sanjosé, Sílvia de , Lollo, Simonetta Di, Diver, W. Ryan , Foretová, Lenka , Ghesquières, Hervé , Glimelius, Bengt , Haïoun, Corinne , Hartge, Patricia, Hjalgrim, Henrik , Holford, Theodore R. , Holly, Elizabeth A., Jackson, Rebecca D. , Kaaks, Rudolph, Kane, Eleanor , Klein, Robert J. , Kraft, Peter , Kricker, Anne , Lan, Qing , Lawrence, Charles , Liebow, Mark , Lightfoot, Tracy, Link, Brian K. , Maynadié, Marc, McKay, James , Melbye, Mads , Molina, Thierry Jo , Monnereau, Alain , Morton, Lindsay M. , Nieters, Alexandra, Novak, Anne J. , Offit, Kenneth , Purdue, Mark P. , Rais, Marco, Riby, Jacques, Roman, Eve , Rothman, Nathaniel , Salles, Gilles , Severi, Gianluca , Severson, Richard K., Skibola, Christine F., Smith, Martyn T. , Southey, Melissa C. , Staines, Anthony , Thompson, Carrie A. , Tilly, Hervé , Tinker, Lesley F. , Tjønneland, Anne , Turner, Jennifer , Vajdic, Claire M. , Vermeulen, Roel , Vijai, Joseph , Vineis, Paolo , Virtamo, Jarmo, Wang, Zhaoming , Weinstein, Stephanie J. , Zheng, Tongzhang, Zucca, Mariagrazia, Clarke, Ann E. , Smith, Alexandra , Bertrand, Kimberly A , Turner, Jennifer , Link, Brian K , Joseph, Vijai , Southey, Melissa C , Brooks-Wilson, Angela R , Vajdic, Claire M , Kane, Eleanor , Tjønneland, Anne , Wang, Zhaoming , Severi, Gianluca , Kraft, Peter , Morton, Lindsay M , De Roos, Anneclaire J , Salles, Gilles A , Wang, Sophia S , Birmann, Brenda M , Roman, Eve , Clavel, Jacqueline , Smith, Alexandra , Bernatsky, Sasha , Ramsey‐Goldman, Rosalind , Albanes, Demetrius , Boffetta, Paolo , Cerhan, James R. , Chanock, Stephen Jacob , Cozen, Wendy , Doǧan, Ahmet , Giles, Graham G. , Habermann, Thomas M. , Kelly, Rachel S. , North, Kari E. , Slager, Susan L. , Smith, Alex, Teras, Lauren R. , Witzig, Thomas E. , Zelenetz, Andrew D. , Zeleniuch‐Jacquotte, Anne , Zhang, Yawei , Angelucci, Emanuele , Klein, Robert

Mayo Clinic

Lupus Science & Medicine | November 13, 2017 | Volume: 4 | Issue: 1 | Pages: e000187

10.1136/lupus-2016-000187 | PMID 29214033 Get It

Objective Determinants of the increased risk of diffuse large B-cell lymphoma (DLBCL) in SLE are unclear. Using data from a recent lymphoma genome-wide association study (GWAS), we assessed whether certain lupus-related single nucleotide polymorphisms (SNPs) were also associated with DLBCL. Methods GWAS data on European Caucasians from the International Lymphoma Epidemiology Consortium (InterLymph) provided a total of 3857 DLBCL cases and 7666 general-population controls. Data were pooled in a random-effects meta-analysis. Results Among the 28 SLE-related SNPs investigated, the two most convincingly associated with risk of DLBCL included the CD40 SLE risk allele rs4810485 on chromosome 20q13 (OR per risk allele=1.09, 95% CI 1.02 to 1.16, p=0.0134), and the HLA SLE risk allele rs1270942 on chromosome 6p21.33 (OR per risk allele=1.17, 95% CI 1.01 to 1.36, p=0.0362). Of additional possible interest were rs2205960 and rs12537284. The rs2205960 SNP, related to a cytokine of the tumour necrosis factor superfamily TNFSF4, was associated with an OR per risk allele of 1.07, 95% CI 1.00 to 1.16, p=0.0549. The OR for the rs12537284 (chromosome 7q32, IRF5 gene) risk allele was 1.08, 95% CI 0.99 to 1.18, p=0.0765. Conclusions These data suggest several plausible genetic links between DLBCL and SLE.
Opioid Neurotoxicity Treated with Intrathecal Drug Delivery System Implant
Wu, Kelly L. , Strand, Jacob J. , Moeschler, Susan M. , Pittelkow, Thomas P.

Mayo Clinic

Journal of Palliative Medicine | November 7, 2017 | Volume: 21 | Issue: 2 | Pages: 126-126

10.1089/jpm.2017.0517 | PMID 29112460 Get It

Tactile Feedback Wearable During a Surgical Simulation Task: Pilot Study Indicates No Distraction, Frustration or Performance Decrement for Users
Lowndes, Bethany R. , Abdelrahman, Amro M. , Yu, Denny , Lachman, Nirusha , Hallbeck, M. Susan , Abdelrahman, Amro M

Mayo Clinic

2017 Design of Medical Devices Conference | October 31, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1115/dmd2017-3462 Get It

With advancements in surgical techniques, patients have experienced improvements in health and recovery outcomes. However, about 87% of laparoscopic surgeons [1] and an increasing number of surveyed allied health professionals [2, 3] report musculoskeletal symptoms. Medical practitioners and human factors engineers have highlighted the “hostile” and “dangerous” operating room (OR) environment [1, 4, 5]. With increasing technology and surgical case complexity, physical demands for surgical team members will continue to increase due to circumstances such as technology restricting posture, taking up working space and more team members working around smaller surgical incisions [6]. There is widespread concern that these medical professionals’ work is unsustainable for safe and healthy patients and surgical team members. Surgical team members can benefit from posture improvement during surgery; however, direct postural feedback may be difficult during their work due to the high visual and auditory stimuli during surgery. The tactile modality has been recently explored as a method to provide additional information without interfering with cognitive resources dedicated to visual and auditory pathways [7]. Tactile devices have successfully been implemented in high-stress environments, e.g., military, healthcare, and rehabilitation with a resulting improvement in performance [8–11]. Vibrotactile feedback has been specifically implemented in the healthcare field for improved performance by 31–75% anesthesiologists during simulated tasks [10]. Additionally, it has contributed to improved postural control in rehabilitation patients[11]. Despite success in other application areas, the potential of tactile devices for improving healthcare workers’ safety and performance remains unexplored. This study is a part of a larger project to design a wearable device that provides realtime vibrotactile feedback for preventing fatigue and musculoskeletal disorders for healthcare workers in the workplace. This specific aim of this study is to measure distraction, frustration, and performance during a surgical simulation task performed with and without vibrotactile feedback. This is a test of initial feasibility of vibrotactile feedback for use in training proper ergonomics for surgical team members. The researchers hypothesize that there will be some distraction with the vibrotactile feedback wearable but no frustration or performance degradation during the basic simulation task.
Human Factors Applications to Mitigate Design Limitations of a Wearable Telemedicine Heart Rate Monitor
Lowndes, Bethany R. , Finnie, Dawn, Hathaway, Julie, Vickers-Douglas, Kristin S., Finnie, Dawn M., Ridgeway, Jennifer L. , Bruce, Charles J. , Hallbeck, M. Susan

Mayo Clinic

2017 Design of Medical Devices Conference | October 31, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1115/dmd2017-3461 Get It

The time required to get a device to market is critical to a successful design, development, and manufacturing process [1]. Achieving status of the first device to market is often a priority for manufacturers and developers. Upon market introduction, it is well known that device performance must meet at least minimum standards in order to provide consumer satisfaction and be a successful product to prevent competitive devices from taking over the market [1]. However, if a design only meets minimum expectations, it may struggle to maintain market control. This demonstrates the tradeoffs of speed-to-market and performance, for which optimization has not been clearly defined [2]. Product performance and usability can be designed in, evaluated and enhanced in order to avoid user errors and achieve optimal profitability. For medical devices, clinical trials are a key step in preparing to take a device to market. Clinical trials can allow for analyses of the effectiveness of the device in the patient care process. For wearable medical devices, patient usability is crucial to patient adherence and safety since the device will be operated by non-medically trained individuals [3,4]. Without adequate usability, adherence and continuity of care are greatly reduced which will reduce the overall effectiveness of the device [5,6]. Human factors principles can best be incorporated in the design process to improve the usability of medical devices and patient safety [5,6,7], specifically for those used in telemedicine [4] and cardiovascular treatment [3]. The objective of this project was to evaluate a telemedicine heart rate monitoring device for patient usability in order to improve the next device’s performance and lead to greater patient adherence for the current version via an improved user manual.
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer
Renfro, Lindsay A. , Hurwitz, Herbert I. , Safran, Howard , Guarino, Michael J., Kim, George P., Hecht, J. Randolph, Weil, Susan C., Heyburn, John, Schweizer, Charles, O’Shannessy, Daniel J., Díaz, Luis A. , Diaz, Luis A , Grothey, Axel , Strosberg, Jonathan , Marshall, John L , Wang, Wenquan

Mayo Clinic

Clinical Cancer Research | October 30, 2017 | Volume: 24 | Issue: 2 | Pages: 316-325

10.1158/1078-0432.ccr-17-1558 | PMID 29084918 Get It

Abstract Purpose: The purpose of this study was to evaluate the safety and efficacy of ontuxizumab (MORAb-004), a monoclonal antibody that interferes with endosialin (tumor endothelial marker-1) function, in patients with chemorefractory metastatic colorectal cancer and to identify a responsive patient population based on biomarkers. Experimental Design: This was a randomized, double-blind, placebo-controlled, phase II study. Patients were randomly assigned in a 2:1 ratio to receive weekly intravenous ontuxizumab (8 mg/kg) or placebo plus best supportive care until progression or unacceptable toxicity. Tissue and blood biomarkers were evaluated for their ability to identify a patient population that was responsive to ontuxizumab. Results: A total of 126 patients were enrolled. No significant difference between the ontuxizumab and placebo groups was evident for the primary endpoint of progression-free survival (PFS), with a median PFS of 8.1 weeks in each group (HR, 1.13; 95% confidence interval, 0.76–1.67; P = 0.53). There were no significant differences between groups for overall survival (OS) or overall response rate (ORR). The most common treatment-emergent adverse events (TEAEs) in the ontuxizumab group (vs. the placebo group, respectively) were fatigue (53.7% vs. 47.5%), nausea (39.0% vs. 35.0%), decreased appetite (34.1% vs. 27.5%), and constipation (28.0% vs. 32.5%). The most common grade 3/4 TEAE in the ontuxizumab group versus placebo was back pain (11.0% vs. 0%). No single biomarker clearly identified patients responsive to ontuxizumab. Conclusions: No benefit with ontuxizumab monotherapy compared with placebo for clinical response parameters of PFS, OS, or ORR was demonstrated. Ontuxizumab was well tolerated. Clin Cancer Res; 24(2); 316–25. ©2017 AACR.
Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma
Tran, Nhan L. , Halperin, Rebecca F. , Phillips, Joanna J. , Kuhn, John G. , Groot, John F. de, Colman, Howard , Wen, Patrick Y. , Mellinghoff, Ingo K. , Butowski, Nicholas , Taylor, Jennie , Clarke, Jennifer , Chang, Susan M. , Molinaro, Annette M. , Maggiora, Gerald M. , Peng, Sen, Liang, Winnie S. , Trent, Jeffrey M. , Berens, Michael E. , Carpten, John D. , Craig, David W. , Prados, Michael D. , Berens, Michael E , Byron, Sara A. , Colman, Howard , Ligon, Keith L , Wen, Patrick Yung , Cloughesy, Timothy F. , Chang, Susan Marina , Berger, Mitchel S. , Molinaro, Annette M. , Nasser, Sara A. , Mellinghoff, Ingo K , Tran, Nhan L

Mayo Clinic

Clinical Cancer Research | October 26, 2017 | Volume: 24 | Issue: 2 | Pages: 295-305

10.1158/1078-0432.ccr-17-0963 | PMID 29074604 Get It

Abstract Purpose: Glioblastoma is an aggressive and molecularly heterogeneous cancer with few effective treatment options. We hypothesized that next-generation sequencing can be used to guide treatment recommendations within a clinically acceptable time frame following surgery for patients with recurrent glioblastoma. Experimental Design: We conducted a prospective genomics-informed feasibility trial in adults with recurrent and progressive glioblastoma. Following surgical resection, genome-wide tumor/normal exome sequencing and tumor RNA sequencing were performed to identify molecular targets for potential matched therapy. A multidisciplinary molecular tumor board issued treatment recommendations based on the genomic results, blood–brain barrier penetration of the indicated therapies, drug–drug interactions, and drug safety profiles. Feasibility of generating genomics-informed treatment recommendations within 35 days of surgery was assessed. Results: Of the 20 patients enrolled in the study, 16 patients had sufficient tumor tissue for analysis. Exome sequencing was completed for all patients, and RNA sequencing was completed for 14 patients. Treatment recommendations were provided within the study's feasibility time frame for 15 of 16 (94%) patients. Seven patients received treatment based on the tumor board recommendations. Two patients reached 12-month progression-free survival, both adhering to treatments based on the molecular profiling results. One patient remained on treatment and progression free 21 months after surgery, 3 times longer than the patient's previous time to progression. Analysis of matched nonenhancing tissue from 12 patients revealed overlapping as well as novel putatively actionable genomic alterations. Conclusions: Use of genome-wide molecular profiling is feasible and can be informative for guiding real-time, central nervous system–penetrant, genomics-informed treatment recommendations for patients with recurrent glioblastoma. Clin Cancer Res; 24(2); 295–305. ©2017 AACR. See related commentary by Wick and Kessler, p. 256
Contemporary Risk Stratification After Myocardial Infarction in the Community: Performance of Scores and Incremental Value of Soluble Suppression of Tumorigenicity‐2
Gerber, Yariv , Weston, Susan A., Enriquez‐Sarano, Maurice , Jaffe, Allan S. , Manemann, Sheila M., Jiang, Ruoxiang , Roger, Véronique L. , Enriquez-Sarano, Maurice , Jaffe, Allan S.

Mayo Clinic

Journal of the American Heart Association | October 23, 2017 | Volume: 6 | Issue: 10 | Pages: No page available

10.1161/jaha.117.005958 | PMID 29054840 Get It

Background Current American Heart Association/American College of Cardiology guidelines recommend the GRACE (Global Registry of Acute Coronary Events) and TIMI (Thrombolysis in Myocardial Infarction) scores to assess myocardial infarction ( MI ) prognosis. Changes in the epidemiological characteristics of MI and the availability of new biomarkers warrant an assessment of the performance of these scores in contemporary practice. We assessed the following: (1) the performance of GRACE and TIMI to predict 1‐year mortality in a cohort of patients stratified by ST ‐segment elevation MI (STEMI) and non‐STEMI ( NSTEMI ) and (2) the incremental discriminatory power of soluble suppression of tumorigenicity‐2, a myocardial fibrosis biomarker. Methods and Results Olmsted County, Minnesota, residents with incident MI (N=1401) were recruited prospectively from November 1, 2002 to December 31, 2012 (mean age, 67 years; 61% men; 79% with NSTEMI ). Baseline data were used to calculate risk scores; soluble suppression of tumorigenicity‐2 was measured in stored plasma samples obtained at index MI . C ‐statistics adapted to survival data were used to assess the discriminatory power of the risk scores and the improvement gained by adding other markers. During the first year of follow‐up, 190 patients (14%) died. The discriminatory performance to predict death was reasonable for GRACE and poor for TIMI , and was generally worse in those with NSTEMI versus those with STEMI. In people with NSTEMI , sequential addition of comorbidities and soluble suppression of tumorigenicity‐2 substantially improved the c ‐statistic over GRACE (from 0.78 to 0.80 to 0.84) and TIMI (from 0.61 to 0.73 to 0.81), respectively (all P ≤0.05). Conclusions Guideline‐recommended scores for risk assessment after MI underperform in contemporary community patients, particularly those with NSTEMI, which now represents most infarcts. Incorporating comorbidities and soluble suppression of tumorigenicity‐2 substantially improves risk prediction, thereby delineating opportunities to improve clinical care.
Iterative Implementation of a Remote Cardiac Patient Monitoring Device using Qualitative Analysis and Human Factors Engineering
Lowndes, Bethany R. , Finnie, Dawn, Hathaway, Julie, Vickers-Douglas, Kristin S., Finnie, Dawn M., Ridgeway, Jennifer L. , Bruce, Charles J. , Hallbeck, M. Susan

Mayo Clinic

Proceedings of the Human Factors and Ergonomics Society Annual Meeting | October 20, 2017 | Volume: 61 | Issue: 1 | Pages: 1081-1085

10.1177/1541931213601874 Get It

Remote monitoring has the potential to improve patient care and satisfaction while reducing the cost of care and burden on the healthcare system for Congestive Heart Failure (CHF) and Atrial Fibrillation (AF) patients. However, the device must be convenient and easy for the population to use correctly. In this study, human factors and qualitative researchers evaluated the use of a remote cardiac monitoring device during a clinical trial with 74 CHF and AF patients. Human factors usability concerns centered on device use and the information presented in the manual. The key themes identified during the qualitative analysis were related to patient education. These findings were incorporated into device design, user manual, or education material updates. This study illustrates how these methods can infuse patient experience into device design to inform continued quality improvement and usability refinement specifically in devices to aid CHF and AF patients without added burden.
A Preliminary Comparison of Three Tourniquet Instructions for Just-in-Time Guidance of a Simulated Tourniquet Application
Lowndes, Bethany R. , Forsyth, Katherine L., Johnson, Carl-Oscar, Abdelrahman, Amro M. , Sztajnkrycer, Matthew D. , Franz, Walter B., Blocker, Renaldo C., Forsyth, Katherine L., Prytz, Erik , Hallbeck, M. Susan , Abdelrahman, Amro M

Mayo Clinic

Proceedings of the Human Factors and Ergonomics Society Annual Meeting | October 20, 2017 | Volume: 61 | Issue: 1 | Pages: 1076-1080

10.1177/1541931213601873 Get It

The American College of Surgeons (ACS) and the Department of Homeland Security (DHS) encourage the use of tourniquets as part of the “Stop the Bleed” campaign. Both have provided instructions for layperson tourniquet application in order to save the life of a hemorrhaging trauma victim. This study sought to compare the impact of using ACS and DHS instructions with manufacturer-provided instructions for the completion of simulated tourniquet application steps. Thirty surgical trainees completed a simulated tourniquet application with one of the three instruction sets. Their completion time and success for each step were measured. Participants that received ACS instructions failed the fewest number of steps (p < 0.01) and completed the task faster (Mean (SD) = 70 (33) seconds) compared to those with the manufacturer-provided instructions (p < 0.01). Tourniquet instruction sets need to be refined in order to optimize the success rate of just-in-time guidance for tourniquet application.